Yahoo
NasdaqGM - Delayed Quote USD

Braveheart Bio, Inc. (BRVE)

26.74 +0.47 (+1.79%)
At close: September 4 at 4:00:01 PM EDT
26.99 +0.25 (+0.93%)
After hours: September 4 at 7:46:50 PM EDT
Chart Range Bar
Loading chart for BRVE
  • Previous Close 26.27
  • Open 25.82
  • Bid --
  • Ask --
  • Day's Range 25.39 - 27.48
  • 52 Week Range 24.31 - 32.00
  • Volume 272,077
  • Avg. Volume 501,357
  • Market Cap (intraday) 1.889B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -1.87
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 45.25

Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM. The company was incorporated in 2024 and is headquartered in San Francisco, California.

www.braveheart.bio

30

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 9/4/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

BRVE
11.46%
S&P 500 (^GSPC)
12.75%

1-Year Return

BRVE
11.46%
S&P 500 (^GSPC)
18.71%

3-Year Return

BRVE
11.46%
S&P 500 (^GSPC)
70.93%

5-Year Return

BRVE
11.46%
S&P 500 (^GSPC)
70.18%

Analyst Insights

View More

Analyst Price Targets

40.00
45.25 Average
26.74 Current
48.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (5yr expected)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -80.23M

  • Diluted EPS (ttm)

    -1.87

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    80.58M

  • Total Debt/Equity (mrq)

    0.93%

  • Levered Free Cash Flow (ttm)

    --

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: